الصفحة الرئيسية>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>PD-166866

PD-166866

رقم الكتالوجGC19279

PD166866 هو مثبط انتقائي لتيروزين كيناز FGFR1 مع IC50 من 52.4 نانومتر

Products are for research use only. Not for human use. We do not sell to patients.

PD-166866 التركيب الكيميائي

Cas No.: 192705-79-6

الحجم السعر المخزون الكميّة
5mg
43٫00
متوفر
10mg
64٫00
متوفر
25mg
128٫00
متوفر
50mg
235٫00
متوفر
100mg
442٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC50 of 52.4 nM.

PD 166866 inhibits human full-length FGFR-1 tyrosine kinase with an IC50 value of 52.4 nM and is characterized as an ATP competitive inhibitor of the FGFR-1. PD 166866 is a potent inhibitor of FGFR autophosphorylation in NIH 3T3 cells expressing endogenous FGFR-1 and in L6 cells overexpressing the human FGFR-1 tyrosine kinase. PD 166866 also inhibits bFGF-induced tyrosine phosphorylation of the 44- and 42-kDa (ERK 1/2) mitogen-activated protein kinase isoforms in L6 cells. Daily exposure of PD 166866 to L6 cells at concentrations from 1 to 100 nM results in a concentration-related inhibition of bFGF-stimulated cell growth for 8 consecutive days with an IC50 value of 24 nM[1].

References:
[1]. Panek RL, et al. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J Pharmacol Exp Ther. 1998 Jul;286(1):569-77.

مراجعات

Review for PD-166866

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PD-166866

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.